88 related articles for article (PubMed ID: 1981310)
41. Antitumor Activity of New Olivacine Derivatives.
Piasny J; Wiatrak B; Dobosz A; Tylińska B; Gębarowski T
Molecules; 2020 May; 25(11):. PubMed ID: 32481577
[TBL] [Abstract][Full Text] [Related]
42. N-methylcarbamate derivatives of ellipticine and olivacine with cytotoxic activity against four human lung cancer cell lines.
Ruckdeschel JC; Modi SP; el-Hamouly W; Portuese E; Archer S
J Med Chem; 1992 Dec; 35(26):4854-7. PubMed ID: 1479585
[TBL] [Abstract][Full Text] [Related]
43. New pyridocarbazole derivatives. Synthesis and their in vitro anticancer activity.
Jasztold-Howorko R; Tylińska B; Biaduń B; Gebarowski T; Gasiorowski K
Acta Pol Pharm; 2013; 70(5):823-32. PubMed ID: 24147360
[TBL] [Abstract][Full Text] [Related]
44. P-glycoprotein gene amplification and expression in multidrug-resistant murine P388 and B16 cell lines.
Capranico G; De Isabella P; Castelli C; Supino R; Parmiani G; Zunino F
Br J Cancer; 1989 May; 59(5):682-5. PubMed ID: 2567607
[TBL] [Abstract][Full Text] [Related]
45. Lysosomal Exocytosis of Olivacine on the Way to Explain Drug Resistance in Cancer Cells.
Wiatrak B; Gębarowski T; Czwojdziński E; Gąsiorowski K; Tylińska B
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682799
[TBL] [Abstract][Full Text] [Related]
46. Antitumor activity of Parthenium hysterophorus and its effect in the modulation of biotransforming enzymes in transplanted murine leukemia.
Mukherjee B; Chatterjee M
Planta Med; 1993 Dec; 59(6):513-6. PubMed ID: 8302949
[TBL] [Abstract][Full Text] [Related]
47. Ellipticine analogues and related compounds as inhibitors of reverse transcriptase and as inhibitors of the efflux pump.
Sharples D; Hajós G; Riedl Z; Csányi D; Molnár J; Szabó D
Arch Pharm (Weinheim); 2001 Sep; 334(8-9):269-74. PubMed ID: 11688136
[TBL] [Abstract][Full Text] [Related]
48. Effects of verapamil on the cellular accumulations and toxicity of several antitumor drugs in 9-hydroxy-ellipticine-resistant cells.
Delaporte C; Charcosset JY; Jacquemin-Sablon A
Biochem Pharmacol; 1988 Feb; 37(4):613-9. PubMed ID: 3342098
[TBL] [Abstract][Full Text] [Related]
49. Resistance to lipophilic cationic compounds in multidrug resistant leukemia cells.
Ramu A; Ramu N
Leuk Lymphoma; 1993 Feb; 9(3):247-53. PubMed ID: 8471985
[TBL] [Abstract][Full Text] [Related]
50. Circumvention of adriamycin resistance by dipyridamole analogues: a structure-activity relationship study.
Ramu N; Ramu A
Int J Cancer; 1989 Mar; 43(3):487-91. PubMed ID: 2925278
[TBL] [Abstract][Full Text] [Related]
51. Effect of new olivacine derivatives on p53 protein level.
Gębarowski T; Wiatrak B; Gębczak K; Tylińska B; Gąsiorowski K
Pharmacol Rep; 2020 Feb; 72(1):214-224. PubMed ID: 32016852
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and biological evaluation of 6-(9-hydroxy-5-methyl (and 5,6-dimethyl)-6H-pyrido[4,3-b]carbazol-1-yl)picolinic amides as new olivacine derivatives.
Landras C; Jasztold-Howorko R; Pierré A; Léonce S; Guilbaud N; Kraus-Berthier L; Guillonneau C; Rolland Y; Atassi G; Bisagni E
Chem Pharm Bull (Tokyo); 1996 Nov; 44(11):2169-72. PubMed ID: 8945783
[TBL] [Abstract][Full Text] [Related]
53. Ultrastructural alterations in plasma membranes from drug-resistant P388 murine leukemia cells.
García-Segura LM; Ferragut JA; Ferrer-Montiel AV; Escriba PV; Gonzalez-Ros JM
Biochim Biophys Acta; 1990 Nov; 1029(1):191-5. PubMed ID: 1977472
[TBL] [Abstract][Full Text] [Related]
54. Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.
Pearce HL; Safa AR; Bach NJ; Winter MA; Cirtain MC; Beck WT
Proc Natl Acad Sci U S A; 1989 Jul; 86(13):5128-32. PubMed ID: 2567994
[TBL] [Abstract][Full Text] [Related]
55. Structural requirements of simple organic cations for recognition by multidrug-resistant cells.
Dellinger M; Pressman BC; Calderon-Higginson C; Savaraj N; Tapiero H; Kolonias D; Lampidis TJ
Cancer Res; 1992 Nov; 52(22):6385-9. PubMed ID: 1358433
[TBL] [Abstract][Full Text] [Related]
56. [The expression of P-glycoprotein in leukemia P388 cells with induced doxorubicin resistance].
Sukhanov VA; D'iakov VL; Lalaev VV; Iakh'iaev AV; Voronkova IM; Donenko FV; Borovkova NB; Moroz LV
Biull Eksp Biol Med; 1991 Mar; 111(3):290-1. PubMed ID: 1675897
[TBL] [Abstract][Full Text] [Related]
57. Ellipticine derivatives interacting with model membranes. Influence of quaternarization of nitrogen-2.
Lempereur L; Sautereau AM; Tocanne JF; Laneelle G
Biochem Pharmacol; 1984 Aug; 33(15):2499-503. PubMed ID: 6466364
[TBL] [Abstract][Full Text] [Related]
58. Isolation of two cellular lines resistant to ribonucleotide reductase inhibitors to investigate the inhibitory activity of 2,2'-bipyridyl-6-carbothioamide.
Nocentini G; Federici F; Armellini R; Franchetti P; Barzi A
Anticancer Drugs; 1990 Dec; 1(2):171-7. PubMed ID: 2131050
[TBL] [Abstract][Full Text] [Related]
59. [Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro].
Sun WC; Han JX; Yang WY; Deng DA; Yue XF
Zhongguo Yao Li Xue Bao; 1992 Nov; 13(6):541-3. PubMed ID: 1302444
[TBL] [Abstract][Full Text] [Related]
60. Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives.
Ripamonti M; Capolongo L; Melegaro G; Gornati C; Bargiotti A; Caruso M; Grandi M; Suarato A
Invest New Drugs; 1996; 14(2):139-46. PubMed ID: 8913834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
